Isodiol International Inc. Announces Partnership with Powerhouse Gym as Preferred CBD Vendor with Iso-Sport
Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), is proud to announce that it has entered into an agreement with Powerhouse Gym, one of the largest health club licensing organization in the world, through the Company’s wholly owned subsidiary, Iso-Sport, to be the preferred vendor of CBD Performance Products offered to its over 1.2 million gym members1.
Powerhouse Gym was founded in 1975 by William and Norman Dabish in Highland Park, Michigan. Today, the Powerhouse Organization operates over 300 locations in 40 states in the U.S. and has a presence in over 20 countries worldwide. Powerhouse and Isodiol debuted the Iso-Sport CBD Performance Products at the annual Powerhouse Conference in Las Vegas, Nevada September 13, 2018. The products will begin to hit the gym locations for sale over the next several weeks.
“It is truly a privilege to have the Powerhouse Gym organization work with the Iso-Sport Team to educate the fitness industry and athletes on the benefits of CBD,” said director of Isodiol and co-founder of Iso-Sport, Marvin Washington. “This is another example of our dedication to bring Iso-Sport CBD Performance Products to athletes around the globe.”
“Powerhouse Gyms believes it works with many leading companies in the supplement industry and is proud to announce Iso-Sport as the preferred CBD Performance Product vendor. We are committed to working with Iso-Sport to tailor a marketing plan that best fits their goals and needs and assure our members have access to these incredible products,” said Powerhouse Gym CEO, Henry Dabish.
For more information on Iso-Sport, please visit: www.iso-sport.com or follow us on social media at:
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.